Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19

Area of Science:

• Infectious Diseases
• Clinical Pharmacology
• Drug Development

Background:

• The COVID-19 pandemic necessitates rapid identification of effective treatments.
• Existing pharmaceutical interventions show limited efficacy, highlighting the need for accelerated evaluation strategies.
• Evaluating drug combinations without prior monotherapy data presents a viable accelerated development option.

Purpose of the Study:

• To propose and describe a strategy for rapidly evaluating antiviral drug combinations for COVID-19 treatment.
• To leverage insights into SARS-CoV-2 pathophysiology and cell cycle dynamics for combination selection.
• To utilize adaptive platform trials for efficient testing of combination therapies.

Main Methods:

• Employing adaptive combination platform trials for simultaneous testing of multiple drug combinations.
• Selecting antiviral combinations based on scientific understanding of the virus and disease pathways.
• Integrating expert advice from infectious disease and clinical pharmacology specialists.

Main Results:

• The described strategy enables rapid assessment of combination therapies.
• This approach allows for the detection of individual drug efficacy within combinations, assuming no antagonism.
• The methodology supports scientific enthusiasm for evaluating repurposed treatments.

Conclusions:

• Adaptive combination platform trials offer an accelerated pathway for COVID-19 treatment development.
• This strategy addresses the urgent need for effective therapies against SARS-CoV-2.
• Combination therapy evaluation, guided by pathophysiology, is a promising approach for pandemic response.